Guangzhou Guolian Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Guangzhou Guolian Technology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 21 (Housewares) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include RENACLIPY. The owner is based in Tianhe Dist.,Guangzhou.
Building B, No. 14 Shengtang St., Cencun
Rm 0620, Zone C, 3F
Tianhe Dist.,Guangzhou 510000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangzhou Guolian Technology Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Guangzhou Guolian Technology Co., Ltd. have?
Guangzhou Guolian Technology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Guangzhou Guolian Technology Co., Ltd. file in?
Guangzhou Guolian Technology Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 21 (Housewares). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Guangzhou Guolian Technology Co., Ltd.'s most well-known trademarks?
Guangzhou Guolian Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as RENACLIPY. These are among 2 currently registered trademarks in the portfolio.
What is Guangzhou Guolian Technology Co., Ltd.'s trademark registration success rate?
Guangzhou Guolian Technology Co., Ltd. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.